symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ICVX,6.55,0.382668,230896,327805230,0,2.28-16.45,0.22,"Icosavax, Inc.",USD,0001786255,US45114M1099,45114M109,NASDAQ Global Select,NASDAQ,Biotechnology,https://icosavax.com,"Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.",Mr. Adam K. Simpson,Healthcare,US,60,206 737 0085,1616 Eastlake Avenue East,Seattle,WA,98102,,0,https://financialmodelingprep.com/image-stock/ICVX.png,2021-07-29,False,False,True,False,False
